Clinical study of dulaptide combined with irbesartan in patients with type 2 diabetes mellitus and hypertension
Objective To analyze the clinical efficacy of dulaptide combined with irbesartan in patients with type 2 diabetes mellitus and hypertension.Methods 98 patients with type 2 diabetes mellitus and hypertension were divided into a control group and an observation group by random number table method,with 49 cases in each group.The control group was treated with basal insulin and irbesartan,and the observation group was treated with dulaglutide and irbesartan.Comparison was made on therapeutic effect,blood glucose indicators[fasting blood glucose,2 h postprandial blood glucose,glycosylated hemoglobin(HbA1c),homeostasis model assessment of insulin resistance index(HOMA-IR),homeostasis model assessment of β-cell function(HOMA-β)],blood pressure,serum homocysteine(Hcy)and brain natriuretic peptide(BNP)between the two groups.Results The total effective rate of the observation group was 95.92%,which was much higher than 77.55%of the control group(P<0.05).After treatment,the fasting blood glucose,2 h postprandial blood glucose,HbA1c,HOMA-IR in both groups decreased compared to those before treatment,while HOMA-β was increased compared to that before treatment;the observation group had fasting blood glucose of(6.41±1.23)mmol/L,2 h postprandial blood glucose of(8.72±1.45)mmol/L,HbA1c of(6.32±0.41)%,HOMA-IR of(3.15±0.25),which were lower than(8.82±1.26)mmol/L,(12.82±2.16)mmol/L,(7.32±0.21)%,(4.12±0.11)in the control group;HOMA-β of(96.52±9.56)in the observation group was higher than(90.58±8.71)in the control group(P<0.05).After treatment,the diastolic blood pressure and systolic blood pressure decreased significantly in both groups;the observation group had diastolic blood pressure of(81.62±5.12)mm Hg(1 mm Hg= 0.133 kPa)and systolic blood pressure of(128.52±5.62)mm Hg,which were lower than(89.92±6.52)and(132.52±4.63)mm Hg in the control group(P<0.05).After treatment,the levels of Hcy and BNP were significantly decreased in both groups;the observation group had Hcy of(14.23±2.15)μmol/L and BNP of(68.82±19.52)pg/ml,which were lower than(17.82±2.11)μmol/L and(89.82±17.54)pg/ml in the control group(P<0.05).Conclusion In patients with type 2 diabetes mellitus and hypertension,dulaptide combined with irbesartan can significantly reduce blood glucose and blood pressure levels,improve insulin resistance and islet beta cell function,and play a certain protective role in target organ function,reduce damage,and has high application value.
Type 2 diabetes mellitusHypertensionDulaptideIrbesartanClinical effect
万方数据
维普
